Dermatological Drugs Market Size, Share & Trends Analysis Report By Dermatological Diseases (Acne, Dermatitis, Psoriasis, Skin Cancer, Others), By Prescription Mode (Prescription Based Drugs, Over Counter Drugs), By Drug Classification (Anti-Inflammatory & Antipruritic Drugs, Corticosteroids, Astringents, Anti-Infective/Antibacterial Drugs, Antifungal Drugs), By Route of Administration (Topical, Oral, Parenteral Administration), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End-User (Hospitals, Speciality Clinics, Cosmetic Centres) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2022-2030

Market Overview

The global dermatological drugs market size was valued at USD 17.09 billion in 2021, and it is anticipated to reach USD 37.85 billion by 2030 at a CAGR of 10.45% during the forecast period(2022-2030). The primary focus of the medical speciality known as dermatology is the diagnosis, prevention, and treatment of a wide variety of skin-related illnesses, including those that affect the hair and nails. Medications employed in the dermatological treatment of skin conditions are referred to as dermatological drugs.

The prevention of skin problems is the primary objective of dermatological medications. Laser therapy, drugs applied topically and taken orally, photodynamic therapy, radiation, vitiligo surgery, and dermatological surgery are all forms of treatment for skin conditions. These dermatological medications are also utilized in the skincare industry to maintain skin characteristics like shine and healthiness.

Market Dynamics

Global Dermatological Drugs Market Drivers

An increasing number of people suffering from dermatologic conditions will drive product demand

An expanding patient population suffering from acne, vitiligo, and dermatitis will almost certainly increase the need for novel solutions on a global scale. For example, the American Association of Dermatology estimates that around 50 million persons in the United States suffered from acne in 2018. As a result, this will invariably increase the demand for products capable of curing illnesses. According to studies conducted in Australia, more than 4 per cent of the population is affected with acne vulgaris over an extended period. The market will likely grow over the forecast period because of the rising frequency of skin diseases and the increased demand for effective treatments.

The Introduction of Therapeutically Effective Drugs to Assist in Development

A stronger influence will probably be made on the global market for dermatology pharmaceuticals by consistently launching novel products focused on customers' needs. For instance, in May 2020, the United States Food and Medicine Administration (FDA) gave Sanofi a license to market its drug Dupixent, which treats atopic dermatitis in children aged 6 to 11. In addition, Cosmedix planned to introduce its Correct Rapid Relief acne treatment in March of that year. In addition, the implementation of marketing tactics for the product, such as the establishment of a website, awareness-raising initiatives, and commercials on television, social media, and other platforms, will contribute to the market expansion during the period covered by the forecast.

Global Dermatological Drugs Market Opportunities

Increasing R&D expenditure in the health care industry and rising technological developments

Rising spending on personal care is a crucial factor driving the market's expansion, along with rising awareness of skin diseases, an increase in the number of patients with vitiligo, dermatitis, and acne, rising demand for dermatological treatments with high awareness among the young population, and an increase in the number of businesses investing in the market. During the projected period, the market for dermatological pharmaceuticals will see additional growth opportunities due to rising technological developments and modernization in healthcare equipment, as well as rising R&D efforts in the healthcare industry and emerging markets.

Global Dermatological Drugs Market Restraints

Side-effects Concerning Improper Product Use to Reduce Product Adoption

Emerging nations account for a significant share of the world's population with dermatological illnesses due to poor diet, pollution, and unhealthy habits like smoking, drinking, etc. Lack of knowledge about skin issues and a higher percentage of illiteracy in low- and middle-income nations have reduced the uptake of items used to treat dermatological conditions. The adverse effects linked to the products are another issue impeding market expansion. For instance, the U.S. FDA issued a warning on using some over-the-counter drugs that can result in potentially fatal allergic disorders. As a result, product acceptance will probably decrease, which will affect the market value of dermatology drugs.

Regional Analysis

The global dermatological drug market is divided into North America, Europe, Asia-Pacific, Central & South America, and the Middle East & Africa.

In 2021, the revenue share held by North America was the highest, at more than 35 percent of total revenue. The United States of America is making valuable contributions to the expansion of the market in the region. The presence of multiple well-established suppliers is one of the most critical factors contributing to the growth of the pharmaceutical market. This location is one of the most promising for launching new healthcare infrastructure and advanced R&D operations in new technologies. These activities help innovate and produce the most appropriate drugs to cure cancer, making this region one of the most promising regions for launching new technology. There has been observed a significant movement in the healthcare industry in the region, away from traditional treatment for providing diagnosis and provision-based health services and toward consumer-driven care as the primary focus. In addition, the market in the region is driven by factors such as the simplicity with which patients may obtain reimbursement for medical expenses and the accessibility of various pharmaceutical products.

During the forecast period, Asia Pacific is anticipated to experience the most significant CAGR growth. The most populous nations globally, such as China and India, are anticipated to have many skin disease sufferers during the projection period. The highest growth in this market is attributed to factors such as health services, life science industry advancements, and increased awareness of skin conditions and their treatments. Additionally, this industry is expanding at a fast rate due to rising incomes and consumer power.

Regarding revenue share, Europe was in second place with more than 30.0 per cent in 2021. The growth of the healthcare sector's substantial investment, the public's increased use of health insurance, and the favourable regulatory environments for the pharmaceutical industry in this area are all factors that contribute to the market's revenue generation.

Segmental Analysis

The global dermatological drugs market is divided into seven parts based on dermatological diseases, prescription mode, drug classification, route of administration, distribution channel, end-user and region. Further, based on dermatological diseases, the market is divided into Acne, Dermatitis, Psoriasis, Skin Cancer and Others. The psoriasis sector dominated the market with a share of 35.0 per cent in 2021. The immune system incorrectly attacks healthy skin cells, which results in psoriasis. Psoriasis is not a disease that spreads quickly. Finger and toe swelling, lower back pain, altered nails, and eye irritation are signs of the disease. Stress, skin injuries, infections, medicines, and heavy drinking can cause psoriasis. Although it affects people of all ages, psoriasis is most common in adults, increasing the global demand for dermatology drugs.

Based on prescription mode, the market is bifurcated into Prescription Based Drugs and Over Counter Drugs. Due to a rise in skin disease prevalence and activities by government and private groups to address skin disease, prescription-based medications were the leading contributor in 2021 and are projected to maintain their lead throughout the projection period.

The market is classified into Anti-Inflammatory & Antipruritic Drugs, Corticosteroids, Astringents, Anti-Infective/Antibacterial Drugs and Antifungal Drugs based on drug classification.

According to the route of administration, the market is divided into Topical, Oral and Parenteral Administration. The parenteral sector dominated the market. The introduction of biologics for treating dermatological disorders is responsible for the segment's dominance.

Based on distribution channels, the market is divided Into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Because of increased patient visits and sales of prescription-based medications for dermatological skin conditions, the hospital pharmacy segment dominates the global market.

According to end-users, the market is segmented into Hospitals, Speciality Clinics and Cosmetic Centres.

The global dermatological drug market is divided into North America, Europe, Asia-Pacific, Central & South America, and the Middle East & Africa. North America dominated the market.

Impact of covid-19

COVID-19 has positive and negative market consequences, as carbon emissions have decreased globally due to the lockout. COVID-19's reduction in emissions is a short-term benefit. Still, when industries and enterprises attempt to recoup some of their financial losses in the first quarter of the year, carbon emissions will rise dramatically. COVID-19 had a negative impact on global recycling efforts. Countries, notably the United States, have halted or decreased recycling programs to focus on collecting additional domestic waste or because services have been disrupted by the virus.

Also, with industries slowly returning to normalcy following the COVID-19 outbreak, this shift in workplace health and safety is expected to increase due to mandatory social distancing and continuous personal care through sanitization to eliminate even the tiniest possibility of COVID-19 spread. COVID-19 has impacted various companies' revenues, and if the lockdown is lifted, companies will turn their attention to operations to make up for their losses.

Recent Developments

• In February 2022, Dr Reddy's sold two derma and respiratory brands to Mankind Pharma.
• In February 2022, Johnson & Johnson discontinued bermekimab development for eczema but stated that it would continue to work on the previously rejected XBiotech medication for hidradenitis suppurativa, a skin condition (HS). A $610 million pretax impairment charge followed the change.
• In May 2022, Affinivax, Inc. (Affinivax), a Cambridge, Boston, Massachusetts-based clinical-stage biopharmaceutical business, was purchased by GSK plc for a $2.1 billion upfront payment and up to $1.2 billion in possible development milestones.